Roche to Acquire LumiraDx's Point of Care Technology for $295M
Shots:
- Roche is set to acquire specific segments of LumiraDx Group, focusing on its Point of Care technology. The transaction is anticipated to conclude by mid-2024, with the integrated entities becoming part of Roche Diagnostics
- Roche will pay $295M, with an additional payment of ~$55M for reimbursing funds related to LumiraDx's Point of Care technology platform. This acquisition is part of a pre-packaged UK administration sale, endorsed by LumiraDx Group's senior secured lender
- The platform has a potential for additional high medical value tests and offers a broad range of immunoassay and clinical chemistry tests
Ref: Roche | Image: LumiraDx
Related News:- LumiraDx Collaborates with AstraZeneca and Everton to Establish a Heart and Lung Screening Hub for its NT-proBNP Test Across England
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Shivani is a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
